Grand River Aseptic Manufacturing Raises Funds for Expansion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Grand River Aseptic Manufacturing Raises Funds for Expansion



Grand River Aseptic Manufacturing (GRAM), a CMO for aseptic pharmaceutical filling, received $9.8 million in capital to expand its facilities, which will create life science jobs in West Michigan. Municipal Employees’ Retirement System (MERS) of Michigan, a nonprofit organization, led the $9.8 million investment round, supported by other Michigan and Indiana-based investors.

“We are delighted with the strong investor response, especially by MERS,” said Tom Ross, GRAM president. “Their considerable support, in combination with the backing from many private investors in our community, is a strong indicator that we’re headed in the right direction. This funding enables us to expand our capabilities, improve our facility, and advance our customer reach, all while creating more highly technical, high-paying jobs in West Michigan.”

Source: Grand River Aseptic Manufacturing

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here